Lv2
198 积分 2020-12-04 加入
Covalent targeted radioligands potentiate radionuclide therapy
3小时前
已完结
A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [ 177 Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA)
9天前
已完结
Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial
9天前
已完结
Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination
1个月前
已完结
Engineered αvβ6-targeting peptide‒BSH conjugates for boron neutron capture therapy of pancreatic ductal adenocarcinoma
3个月前
已关闭
Recommendations for the dosimetry of patients undergoing therapy with radiopharmaceuticals that include 177Lu
3个月前
已完结
A high-throughput selection system for fast-acting covalent protein drugs
4个月前
已完结
An Overview of Current New Approach Methodologies for Developmental Toxicity and the Current Research Gaps
4个月前
已关闭
STARLITE 1: Phase 1b/2 Study of Combined 177Lu-Girentuximab plus Cabozantinib and Nivolumab in Treatment-naïve Patients with Advanced Clear-cell Renal Cell Carcinoma
4个月前
已完结
A Phase I/II Study of [
4个月前
已关闭
皖公网安备34019202002308
